A Phase II Multicenter Clinical Study of Improved Short-course Radiotherapy Combined With CAPOX and PD-1 Monoclonal Antibody for Locally Advanced Mid-low Rectal Cancer
Conditions: Mid-low Rectal Cancer Interventions: Radiation: Short-course Radiotherapy; Drug: Tislelizumab; Drug: capecitabine; Drug: Oxaliplatin Sponsors: Fujian Cancer Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Eloxatin | Hospitals | Rectal Cancers | Research | Study | Xeloda